Abdala (vaccine)
Abdala (vaccine)
Abdala (pronunciation: /æbˈdɑːlə/) is a COVID-19 vaccine developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba. It is named after a patriotic poem by José Martí, a Cuban national hero.
Etymology
The name "Abdala" comes from a poem written by José Martí in 1869. The poem is about a prince who sacrifices himself for his people, reflecting the spirit of the vaccine's development during the COVID-19 pandemic.
Development and Efficacy
The Abdala vaccine is a three-dose protein subunit vaccine. It was developed by the CIGB and has shown an efficacy rate of 92.28% after the third dose in Phase III trials. The vaccine does not require extreme cold storage, making it a viable option for countries with limited resources.
Authorization and Distribution
As of July 2021, the Abdala vaccine has been authorized for emergency use in Cuba and Venezuela. It is one of the two domestically produced vaccines in Cuba, the other being Soberana 02.
Related Terms
- COVID-19 pandemic
- Vaccine
- Center for Genetic Engineering and Biotechnology (CIGB)
- José Martí
- Soberana 02
External links
- Medical encyclopedia article on Abdala (vaccine)
- Wikipedia's article - Abdala (vaccine)
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski